There are challenges in bringing new forms of treatments to fruition but increasing the ability to supply specialized medicines throughout the world is also a critical opportunity. Speed is a key component in achieving these goals. Biologics present additional hurdles: They are capital-intensive, highly regulated, science-focused, and require a deep talent base.
To address these challenges, Janssen has partnered with local universities to develop industry talent, providing undergraduate and post-graduate work placements, as well as designing and delivering technical modules as part of undergraduate courses. Janssen has also forged relationships with other operating companies near the Cork facility to encourage government support for a biologics cluster in Ireland. Janssen will continue to work globally with external partners to make products, or perform intermediate steps, to ensure medicines are delivered to patients compliantly, on time, and at a fair price.
The world of pharmaceutical products continues to evolve, and with it, the factories of the future that are developing next-generation medicines need to have the ability to be reliable, compliant, and cost-effective producers of therapies for patients. Manufacturing facilities must be designed and operated for agile response to market demands and to volume changes. Janssen will continue to work globally with their partners to accommodate innovative technologies, focus on end-to-end solutions, and ensure that the focus stays on sustainable solutions for the patient.